Health
Moderna, Merck Cancer Vaccine Shows Promise
A late-stage trial of a personalized mRNA-based cancer vaccine from Moderna and Merck has shown success in preventing melanoma recurrence. The results could lead to significant advancements in cancer treatment.
Coverage timeline — 1 article
The Hill
An experimental personalized mRNA-based cancer vaccine from Merck and Moderna was successful at preventing melanoma from returning or spreading in a late-stage trial of high risk patients, the companies announced Wednesday. The positive results mean a potentially life-extending treatment is one st
2026-08-19 14:54 UTC